Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

“Not All Amyloid Beta Therapeutics Are Created Equal”

Written by: | mediasite@prnewswire.com | Dated: Thursday, January 25th, 2018

 

ProMIS Neurosciences Issues White Paper Entitled: “Not All Amyloid Beta Therapeutics Are Created Equal”

 

ProMIS Neurosciences Lead Product Candidate for Alzheimer’s Disease Shows Improved Therapeutic Potency versus other Amyloid Beta-Directed Antibodies

TORONTO and CAMBRIDGE, MA, Jan. 25, 2018 /CNW/ – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced it has issued a new scientific white paper entitled: ‘Not all Amyloid Beta Therapeutics are Created Equal’. This is one of a series of commentaries from the ProMIS scientific team offering insight on Alzheimer’s disease (AD) science and the Company’s emerging product portfolio.

This white paper outlines recent scientific progress indicating that soluble, low molecular weight (LMW) toxic amyloid beta (Ab) oligomers, are the ‘true pathogen’ in Alzheimer’s disease. These LMW toxic oligomers typically consist of twelve (dodecamer), four (tetramer) or two (dimer) strands of Ab. The clinical activity of Ab-directed antibodies seems correlated with their ability to more selectively target toxic oligomers, consistent with the greater therapeutic activity seen in clinical trials with aducanumab (Biogen) compared to bapineuzumab (Pfizer, Johnson & Johnson). Results of studies with soluble brain material from AD patients recently conducted in the laboratory of ProMIS Chief Scientific Officer, Dr. Neil Cashman, indicate that humanized PMN310 shows significantly greater binding than aducanumab (~1.5-2 fold) to the toxic oligomer-enriched LMW fraction of AD brain extract. 

Commenting on the white paper, Dr. Johanne Kaplan, ProMIS Chief Development Officer, stated: “Recent scientific data indicate that a best in class antibody therapeutic for Alzheimer’s disease should target LMW toxic oligomers without binding Ab monomers (reduced efficacy) or plaque (increased risk of brain swelling). Preclinical results to date indicate that PMN310 displays such a product profile and has the potential for safe administration of higher effective doses and greater therapeutic potency.” 

The white paper can be accessed directly on the ProMIS Neurosciences website by clicking on the link below:

http://bit.ly/2BqyqTl

 

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a development stage biotechnology company focused on discovering and developing precision medicine therapeutics to treat neurodegenerative diseases, in particular Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform — ProMIS™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS.  ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN.TO, and on the OTCQB Venture Market under the symbol ARFXF.

For further information please consult the Company’s website at: www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.  This news release contains certain “forward-looking statements” within the meaning of Canadian securities legislation. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects”, “plans”, “anticipates”,  believes”, “intends”, “estimates”, “projects”, “aims”, “potential”, “goal”, “objective”, “prospective”, and similar expressions, or that events or conditions “will”, “would”, “may”, “can”, “could” or “should” occur. Forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except as required by the securities disclosure laws and regulations applicable to the Company, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

SOURCE ProMIS Neurosciences Inc.

 


ProMIS Neurosciences Inc. (CNW Group/ProMIS Neurosciences Inc.)

For further information: For media inquiries, please contact: David Schull, RussoPartners/LLC, David.Schull@russopartnersllc.com, Tel. 858 717-2310; For Investor Relations please contact: Alpine Equity Advisors, Nicholas Rigopulos, President, nick@alpineequityadv.com, Tel. 617 901-0785; Dr. Elliot Goldstein, President and Chief Executive Officer, ProMIS Neurosciences Inc., Tel. 415 341-5783, Elliot.goldstein@promisneurosciences.com

 

 

PR Newswire source:

https://www.prnewswire.com/news-releases/promis-neurosciences-issues-white-paper-entitled-not-all-amyloid-beta-therapeutics-are-created-equal-671069133.html

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom